Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting®
Dateline City:
KENILWORTH, N.J.
Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of results from an integrated analysis
of patients with compensated liver cirrhosis (Child-Pugh class A) from
six Phase 2 and 3 clinical trials evaluating the efficacy and safety of
the investigational once-daily tablet elbasvir/grazoprevir1
(50mg/100mg) with or without ribavirin (RBV) in patients with chronic
hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD NYSE:MRK Source Type: news
More News: Child Development | Children | Cirrhosis | Clinical Trials | Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Urology & Nephrology